![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cell Genesys (MM) | NASDAQ:CEGE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.327 | 0 | 01:00:00 |
As filed with the Securities and Exchange Commission on October 14, 2009
Registration No. 333-91796
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Cell Genesys, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of
|
|
94-3061375 (I.R.S. Employer Identification Number) |
400 Oyster Point Boulevard, Suite 525
South San Francisco, California 94080
(650) 266-3000
(Address of Registrants Principal Executive Office) (Zip Code)
2002 Employee Stock Purchase Plan
2001 Nonstatutory Stock Option Plan
(Full title of the plan)
Stephen M. Simes
Vice Chairman, President and Chief Executive Officer
BioSante Pharmaceuticals, Inc.
111 Barclay Boulevard
Lincolnshire, Illinois 60069
(847) 478-0500
(Name and Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)
Copies requested to:
Amy E. Culbert, Esq.
Oppenheimer Wolff & Donnelly LLP
45 South Seventh Street, Suite 3300
Minneapolis, Minnesota 55402-1509
(612) 607-7287
DEREGISTRATION OF SECURITIES
On July 2, 2002, Cell Genesys, Inc., a Delaware corporation (Cell Genesys), filed with the Securities and Exchange Commission a registration statement on Form S-8 (Registration No. 333-91796) (the Registration Statement) registering the sale of up to 200,000 shares of common stock, par value $0.001 per share, of Cell Genesys (Common Stock) pursuant to the Cell Genesys, Inc. 2002 Employee Stock Purchase Plan and up to 3,000,000 shares of Common Stock pursuant to the Cell Genesys, Inc. 2001 Nonstatutory Stock Option Plan.
On October 14, 2009, Cell Genesys was merged with and into BioSante Pharmaceuticals, Inc., a Delaware corporation (BioSante), with BioSante continuing as the surviving company (the Merger). The Merger was effectuated pursuant to the terms of an Agreement and Plan of Merger, dated as of June 29, 2009, by and between Cell Genesys and BioSante.
As a result of the Merger, the offering pursuant to the Registration Statement has been terminated. In accordance with undertakings made by Cell Genesys in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities which remain unsold at the termination of the offering, Cell Genesys hereby removes from registration the Cell Genesys common stock registered but unsold under the Registration Statement.
2
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lincolnshire, State of Illinois, on October 14, 2009.
|
CELL GENESYS, INC. |
|
|
|
|
|
|
|
|
By: |
/s/ Stephen M. Simes |
|
|
Stephen M. Simes |
|
|
Vice Chairman, President and Chief Executive Officer (principal executive officer) of BioSante Pharmaceuticals, Inc., as successor in interest to Cell Genesys, Inc. |
|
|
|
|
|
|
|
By: |
/s/ Phillip B. Donenberg |
|
|
Phillip B. Donenberg |
|
|
Chief Financial Officer, Treasurer and Secretary |
|
|
(principal financial and accounting officer) of BioSante Pharmaceuticals, Inc., as successor in interest to Cell Genesys, Inc. |
Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement on Form S-8 has been signed on October 14, 2009, by the following persons in the capacities indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Stephen M. Simes |
|
Vice Chairman, President and Chief Executive Officer |
|
October 14, 2009 |
Stephen M. Simes |
|
|
|
|
|
|
|
|
|
/s/ Phillip B. Donenberg |
|
Chief Financial Officer, Treasurer and Secretary |
|
October 14, 2009 |
Phillip B. Donenberg |
|
|
|
|
|
|
|
|
|
/s/ Louis W. Sullivan, M.D. |
|
Chairman of the Board |
|
October 14, 2009 |
Louis W. Sullivan, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Louis W. Sullivan, M.D. |
|
Director |
|
October 14, 2009 |
Louis W. Sullivan, M.D. |
|
|
|
|
|
|
|
|
|
|
|
Director |
|
|
Peter Kjaer |
|
|
|
|
3
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Ross Mangano |
|
Director |
|
October 14, 2009 |
Ross Mangano |
|
|
|
|
|
|
|
|
|
/s/ John T. Potts, Jr., M.D. |
|
Director |
|
October 14, 2009 |
John T. Potts, Jr., M.D. |
|
|
|
|
|
|
|
|
|
/s/ Edward C. Rosenow, III, M.D. |
|
Director |
|
October 14, 2009 |
Edward C. Rosenow, III, M.D. |
|
|
|
|
|
|
|
|
|
/s/ Stephen A. Sherwin, M.D. |
|
Director |
|
October 14, 2009 |
Stephen A. Sherwin, M.D. |
|
|
|
|
4
1 Year Cell Genesys (MM) Chart |
1 Month Cell Genesys (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions